

Latvia

Recent and planned developments in pharmaceutical policies 2018

Special topic: national incentives and derogatory procedures for orphan medicines

CHANGES IN PRICING

- Until 1st September 2018 the representatives of MAH had to reduce prices of the interchangeable medicines whose price per DDD or TDD was more than 100% higher than the price of the cheapest medicine within INN. The prices of the mentioned medicines had to be reduced to 100% price difference threshold or by 20%. The next round of price reductions is anticipated on 1st September 2019.

CHANGES IN REIMBURSEMENT

- *15/08/2018*: new diagnoses with 100% reimbursement rate are included in the list of diseases for which medicines are reimbursed: Primary pulmonary hypertension, Osteogenesis imperfecta, Lung transplant status
- *15/08/2018*: reimbursement rate increased:
 - from 50% to 100% for *Sarcoidosis, Hypersensitivity pneumonitis due to organic dust, Other interstitial pulmonary diseases, Huntington disease, Motor neuron disease*;
 - from 75% to 100% for *Disorders of mineral metabolism*.
- *01/01/2019*: the following new diagnoses with 100% reimbursement rate will be included in the list of diseases for which medicines are reimbursed: *Immunodeficiency associated with other major defects, Common variable immunodeficiency, Other immunodeficiencies, Other urticaria, Echinococcosis, Cysticercosis*

OTHERS CHANGES

No changes

SPECIAL TOPIC: National Incentives and Derogatory Procedures for Orphan Medicines

- Action Plan in the Field of Rare Diseases 2017-2020 (early and timely diagnostics; providing necessary treatment; registry of patients; Coordination Centre for Rare Diseases)
- Availability and funding of orphan medicines:
 - Positive List: State budget Program for reimbursable medicines
 - Childrens Clinical University Hospital: special program for reimbursement of medicines for patients with rare diseases
- HTA and pricing of orphans:
 - Positive List: general procedure, no special arrangements
 - Special program for reimbursement of medicines for patients with rare diseases: HTA – general procedure, price is set by tendering
- Reimbursement:
 - Positive List: reimbursement is diagnosis related, the Cabinet of Ministers sets the reimbursement rate
 - Special program for reimbursement of medicines for patients with rare diseases: 100% reimbursement